Wyoming biologics regulations.
Who may administer PRP, exosomes and stem cells in Wyoming, and which agencies to check.

Who may administer biologics in Wyoming?
In Wyoming, only licensed physicians (MDs/DOs) are permitted to administer stem cell injections or biologic therapies.
Official sources
Wyoming compliance guide.
FDA Compliance
The U.S. Food and Drug Administration (FDA) governs human cells, tissues, and cellular- and tissue-based products (HCT/Ps) to protect patient safety. For Wyoming clinics offering biologics, key federal compliance guidelines include:
- Following the FDA’s HCT/P guidelines to determine if your product qualifies under Section 361 of the Public Health Service Act for minimal oversight.
- Submitting premarket approval or an investigational new drug application (IND) if the product is regulated as a drug or biologic.
- Complying with Good Tissue Practice (GTP) standards to ensure product integrity and reduce contamination risk.
Wyoming State Regulations
Alongside federal guidelines, Wyoming clinics must adhere to state-specific regulations. Wyoming does not impose additional strict oversight on regenerative medicine, but practitioners are encouraged to verify compliance with Wyoming’s Department of Health for any updates or standards applicable to biologics.
Provider Qualifications
In Wyoming, only licensed physicians (MDs/DOs) are permitted to administer stem cell injections or biologic therapies. For more detailed licensing requirements, visit the Wyoming Professional Licensing Boards page for credentialing requirements and pathways.
Patient Informed Consent
Informed consent is critical in biologic therapy to ensure patient awareness of the risks, benefits, and experimental nature of certain treatments. Wyoming practitioners should include the following in consent forms:
- A summary of potential risks and anticipated benefits
- A disclosure if the therapy is experimental or investigational
- Available alternative treatments
- Limitations of the therapy and a disclaimer if it is not FDA-approved for a specific use. Thorough consent documentation ensures transparency with patients and aligns with Wyoming patient rights regulations.
Additional Compliance Considerations
Pre-Treatment and Post-Treatment Protocols
Implement pre-treatment screenings and post-treatment follow-ups as part of patient management to monitor for adverse reactions and track patient outcomes. Consistent protocols also align with both FDA and Wyoming best practices for patient safety.
Standard Operating Procedures (SOPs)
Develop and document SOPs for all procedures related to biologic handling, storage, and administration to maintain quality standards. Compliance with Good Manufacturing Practice (GMP) guidelines is advised to prevent contamination and ensure consistent results.
Medical Liability Insurance
Verify that your clinic carries comprehensive medical liability insurance, covering biologic and stem cell treatments specifically. Insurance is crucial to manage potential risks associated with these therapies.
Marketing Compliance
All marketing materials must accurately reflect the capabilities and limitations of biologic therapies. Avoid promotional claims that may imply guaranteed results or misrepresent the experimental nature of certain treatments, as non-compliant marketing can attract regulatory attention from both FDA and Wyoming state agencies.
This guide is a general summary to help clinics understand compliance requirements for biologics in Wyoming. It is not legal advice. Regulations change; consult legal counsel and the agencies above before acting on it.
Wyoming: common questions.
Who can administer stem cells, PRP and exosomes in Wyoming?
Are stem cell and exosome therapies FDA-approved in Wyoming?
Do I need an IRB-approved study to offer biologics in Wyoming?
How do I start offering biologics in Wyoming?
Practising in Wyoming? Start with the webinar.
Live on Zoom, Tuesdays at 12:00 PM ET. See how the model works before you commit to anything.